Zheng C, Liu S, Feng J, Zhao X. Prognostic Value of Inflammation Biomarkers for Survival of Patients with Neuroblastoma. Cancer Manag Res. 2020 Apr 1;12:2415-2425. doi: 10.2147/CMAR.S245622. PMID: 32280277; PMCID: PMC7132027.
Free full-text access.
“The association between inflammation and cancer also promoted the investigation of the prognostic role of inflammation-based biomarkers for cancer patients. In recent years, several blood inflammation biomarkers or inflammation-based scores have been found to be predictive of survival for multiple types of cancers. These potential prognostic inflammation indicators include C-reactive protein (CRP), albumin (ALB), Glasgow Prognostic Score
(GPS), C-reactive protein to albumin ratio (CAR), neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and systemic immune-inflammation index (SII).4–30″
“The survival curves of the prognostic inflammation biomarkers for NB patients were generated by Kaplan–Meier method as is shown in Figure 3. Patients with elevated
CRP level had significantly worse OS than those with normal CRP level (Figure 3A, p = 0.002). Serum ALB level could not significantly stratify NB patients into two different survival groups (Figure 3B, p =0.1). Patients with higher CAR value had significantly worse OS than those with lower CAR value (Figure 3C, p < 0.001). Patients with elevated GPS score had significantly worse OS than those with normal GPS score (p = 0.001, p = 0.009 and p < 0.001 for GPS, mGPS and Hs-mGPS, respectively) (Figure 3D–F)”
